Business Wire

FL-BIEDERMANN-MOTECH

21.9.2021 12:02:07 CEST | Business Wire | Press release

Share
Biedermann Motech To Further Expand MOSS VRS® - The Next Generation Pedicle Screw Technology™ By Adding MOSS Modularity™

Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 35 years, today announced that its MOSS VRS® Pedicle Screw Platform, the most advanced system on the market today, is now available as a fully modular solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005274/en/

The MOSS VRS System features Next Generation Pedicle Screw Technology™, which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery. This provides surgeons unmatched intraoperative real-time options using a single, highly functional implant.

In contrast to traditional pedicle screw systems, which include a wide range of different screw types, the MOSS VRS Pedicle Screw can be locked and unlocked as and when required by the surgeon during complex correction and reconstruction maneuvers.

By adding MOSS Modularity™ to this unique functionality, surgeons now will have the option to attach the modular MOSS VRS tulip heads after the pedicle screw shafts have been placed, allowing even more advanced and versatile surgical techniques.

”Over 30 years after the introduction of the MOSS System, the world’s first polyaxial pedicle screw, we are excited to continue to lead the advancement of posterior screw systems with the further expansion of our MOSS VRS platform,” said Markku Biedermann, President & CEO of Biedermann Motech, Inc.

The unique and proprietary technologies of the MOSS VRS System are licensed from Biedermann Technologies GmbH & Co. KG, a company which holds a broad and extensive patent and technology portfolio, and are exclusively available through Biedermann Motech.

Biedermann Motech will showcase the MOSS VRS System at the upcoming North American Spine Society (NASS) Annual Meeting in Boston, MA, September 22-24, 2021 at booth #2349.

About Biedermann Motech

Biedermann Motech is a mid-sized, family owned group of companies with headquarters in Germany (Villingen-Schwenningen) and the USA (Miami) whose roots go back to 1916. Since then, the focus has been on working in synergy with world-class surgeons to solve significant clinical challenges through the development of next generation technologies. The core competency is the development, production, and distribution of innovative implants and instruments for spinal and extremity surgery. Biedermann Motech researches, develops, manufactures, and distributes high-quality implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. For more information about Biedermann Motech, please visit: www.biedermann.com .

Follow us:

LinkedIn: https://www.linkedin.com/company/biedermannmotech

Instagram: https://www.instagram.com/biedermannmotech/

About Biedermann Technologies

Biedermann Technologies GmbH & Co. KG (www.biedermann-technologies.com ) is a privately held company based in Germany (Donaueschingen) and is the owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 25 years, Biedermann Technologies has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye